60 mg Tablets
60 mg products are central to rheumatoid arthritis and ankylosing spondylitis treatment and are also used where osteoarthritis symptoms require dose escalation.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (60 mg, 90 mg, 120 mg), By Application (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Others), By End User (Hospitals & Specialist Clinics, Primary Care / Community Practices, Homecare / Long-Term Users), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Manufacturer Type (Originator / Branded Suppliers, Large Generic Manufacturers, Regional Generic Manufacturers), and Regional Forecast, 2026-2034
The global etoricoxib tablet market was valued at USD 1.20 billion in 2025 and is estimated at USD 1.30 billion in 2026. The market is projected to reach USD 2.50 billion by 2034, representing an 8.5% CAGR during 2026–2034.
Etoricoxib is a selective cyclooxygenase-2 inhibitor used for symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gout and selected acute pain conditions in markets where it is authorized. The commercial tablet market is largely generic outside the originator Arcoxia brand and is supplied in several strengths tailored to chronic and acute indications.
The addressable musculoskeletal burden is large. WHO estimates 528 million people were living with osteoarthritis and 18 million with rheumatoid arthritis in 2019. These chronic conditions create a broad demand base for oral anti-inflammatory treatment, although prescribing is influenced by cardiovascular, renal and gastrointestinal risk and the need to use the lowest effective dose for the shortest appropriate duration.
Current product availability demonstrates a mature multi-supplier market. The UK electronic medicines compendium lists dozens of etoricoxib products from Organon, Aurobindo/Milpharm, Viatris, Zentiva, Glenmark, Strides, Krka and other suppliers. Arcoxia and generic labels cover 30 mg, 60 mg, 90 mg and 120 mg products, while the report’s core commercial segmentation focuses on 60 mg, 90 mg and 120 mg tablets.
Source: WHO osteoarthritis; WHO musculoskeletal conditions; Arcoxia SmPC; emc etoricoxib product list; Aurobindo etoricoxib leaflet.
The study defines the global etoricoxib tablet market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | 60 mg; 90 mg; 120 mg |
| By Application | Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis; Others |
| By End User | Hospitals & Specialist Clinics; Primary Care / Community Practices; Homecare / Long-Term Users |
| By Distribution Channel | Hospital Pharmacies; Retail Pharmacies; Online Pharmacies |
| By Manufacturer Type | Originator / Branded Suppliers; Large Generic Manufacturers; Regional Generic Manufacturers |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | India; China; Japan; South Korea; United Kingdom; Germany; France; Italy; Spain; Brazil; Mexico; South Africa; GCC countries and other authorized markets |
| Key Market Players | Organon; Aurobindo Pharma; Viatris; Zentiva; Glenmark Pharmaceuticals; Strides Pharma; Krka; Sun Pharmaceutical Industries; Cipla; Dr. Reddy's Laboratories; Qilu Pharmaceutical |
The market includes prescription oral etoricoxib tablets supplied for authorized musculoskeletal and acute-pain indications. Revenue covers the 60 mg, 90 mg and 120 mg tablet strengths and branded or generic finished-dose products within the defined market scope.
Other COX-2 inhibitors, conventional NSAIDs, combination products in which etoricoxib is not the defining active ingredient and non-oral formulations are outside the core revenue boundary.
WHO estimates 528 million people worldwide were living with osteoarthritis in 2019. Long-duration pain and stiffness management create recurring demand for oral anti-inflammatory medicines where etoricoxib is authorized.
WHO estimates 18 million people live with rheumatoid arthritis, while NICE recommends NSAID therapy as initial pharmacologic treatment for axial spondyloarthritis-related pain. Etoricoxib is one of several COX-2 selective options available in authorized markets.
The UK electronic medicines compendium lists numerous etoricoxib products across several generic suppliers. This increases access but compresses pricing and shifts competition toward pharmacy coverage, tender access and manufacturing cost.
Current product information recommends using the lowest dose that controls symptoms and avoiding longer treatment than necessary because cardiovascular risk can increase with prolonged exposure and higher doses.
Etoricoxib is broadly commercialized in Europe, Asia and other international markets but is not a universal global standard in every country. Regional regulatory status therefore materially affects market size and competitive structure.
Source: WHO osteoarthritis; WHO musculoskeletal; NICE spondyloarthritis; Arcoxia SmPC; emc product list.
Multiple UK generic companies currently list 60 mg, 90 mg and 120 mg products, increasing competition with the Arcoxia brand and supporting lower-cost access.
Current product information recommends 60 mg once daily for rheumatoid arthritis and ankylosing spondylitis, with escalation to 90 mg in selected patients with inadequate symptom relief.
Osteoarthritis labeling supports lower daily dosing and emphasizes down-titration where clinically appropriate, reinforcing the broader pain-management trend toward minimizing long-term NSAID exposure.
Prescription e-pharmacy growth in Asia and other regions improves refill convenience for chronic users and increases brand visibility among generic manufacturers.
Because active ingredient and core dosing are standardized, manufacturers compete mainly through quality, pack size, pharmacy availability, patient information and institutional relationships rather than differentiated clinical efficacy.
Source: Arcoxia SmPC; Aurobindo leaflet; Viatris etoricoxib SmPC; emc ingredient list.
Etoricoxib is a mature oral small-molecule therapy. Commercial differentiation is therefore concentrated in dosage strength, tablet manufacturing, packaging and supply rather than new drug-delivery technology.
60 mg products are central to rheumatoid arthritis and ankylosing spondylitis treatment and are also used where osteoarthritis symptoms require dose escalation.
90 mg tablets support selected patients with inadequate control on 60 mg and are also used in certain acute-pain indications.
120 mg is used for acute gout in current labeling for a limited treatment period.
Manufacturers compete through pack-size flexibility, moisture protection, pharmacy supply and cost-efficient manufacturing.
Source: Arcoxia SmPC; Aurobindo leaflet.
By type, the market is segmented into 60 mg, 90 mg and 120 mg tablets. The 60 mg strength is the leading segment because it is used across several chronic inflammatory indications and often serves as the standard ongoing dose.
The 60 mg tablet is widely used for rheumatoid arthritis and ankylosing spondylitis and can be used in osteoarthritis when lower dosing does not provide sufficient symptom control.
The 90 mg strength is used for selected patients requiring greater symptom control and for certain acute pain settings with duration limits.
The 120 mg strength is primarily associated with acute gout and is used for short treatment periods because higher-dose exposure increases safety considerations.
The 60 mg segment is expected to remain the largest because it balances efficacy and chronic-use practicality, while 90 mg and 120 mg retain important indication-specific roles.
By application, the market is segmented into osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and other uses. Osteoarthritis is the leading application because its global prevalence is far larger than other inflammatory arthritis categories.
WHO estimates 528 million people live with osteoarthritis. Etoricoxib is used for symptomatic pain and inflammation management in authorized markets.
Rheumatoid arthritis affects 18 million people worldwide and requires long-term disease-modifying treatment plus symptomatic pain control in selected patients.
NSAIDs are a standard first-line symptomatic therapy in axial spondyloarthritis, creating a clinically relevant etoricoxib use case.
Other use includes acute gout and selected acute pain such as postoperative dental pain according to local product labeling.
Osteoarthritis will remain the largest application, while rheumatoid arthritis, ankylosing spondylitis and acute gout provide important specialist and higher-dose demand.
By end user, demand is segmented across hospitals and specialist clinics, primary-care or community practices, and homecare or long-term users. Primary-care and community prescribing represents the broadest ongoing demand base for chronic osteoarthritis and musculoskeletal pain.
Rheumatology, orthopedics and pain clinics manage higher-risk patients, treatment escalation and complex inflammatory disease.
Primary-care clinicians manage large osteoarthritis populations and ongoing NSAID prescriptions where etoricoxib is appropriate.
Most tablet consumption occurs outside institutional settings after prescription, with chronic users generating repeat pharmacy demand.
Primary-care prescribing and long-term home use will remain the largest volume base, while specialist clinics influence dose selection and risk management.
By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Retail pharmacies remain the leading channel because etoricoxib is an outpatient oral prescription medicine with recurring refill demand.
Hospital pharmacies support prescriptions initiated by rheumatology, orthopedics and pain specialists and serve inpatient or hospital-affiliated outpatient care.
Community pharmacies provide the largest recurring access point for chronic users and carry multiple branded and generic strengths.
Prescription e-pharmacies improve refill convenience and price comparison in markets where digital dispensing is permitted.
Retail pharmacies will remain the largest distribution channel, while online pharmacy should gain share as digital prescription fulfillment expands.
By manufacturer type, the market is segmented into originator or branded suppliers, large generic manufacturers and regional generic manufacturers. Large generic manufacturers dominate unit volume because the molecule is mature and widely off patent.
Organon markets Arcoxia in multiple international markets and maintains brand recognition despite broad generic competition.
Aurobindo, Viatris, Zentiva, Glenmark, Strides and other large generics compete through scale, regulatory dossiers and pharmacy access.
Regional suppliers compete in tender and retail markets through low-cost manufacturing and local distribution relationships.
Large generic manufacturers are expected to remain the dominant supplier group, while the originator retains brand value in selected markets.
Regional demand reflects regulatory authorization, arthritis burden, generic manufacturing and pharmacy access. Asia-Pacific is the largest regional market, with Europe also representing a mature and highly competitive etoricoxib market.
Asia-Pacific leads through large musculoskeletal disease populations, strong generic manufacturing in India and broad use of etoricoxib across multiple authorized markets.
Europe has established Arcoxia and generic etoricoxib products across many national markets, with strong regulatory oversight and pharmacy substitution.
Brazil, Mexico and other markets support COX-2 selective NSAID demand through retail and institutional channels.
GCC and selected African markets use imported and locally distributed etoricoxib products, with access varying by regulatory authorization and reimbursement.
The regional market is smaller because etoricoxib is not a broadly established prescription product across North America in the same way as in Europe and Asia.
Source: emc product list; WHO osteoarthritis; WHO musculoskeletal.
Etoricoxib is a prescription COX-2 selective NSAID whose commercial use depends strongly on national authorization and product-specific cardiovascular, renal and gastrointestinal risk management.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Prescription-only status | Current UK products are prescription-only medicines. | Keeps clinician assessment central to use. |
| Dose limitation | Current labeling sets indication-specific maximum doses and short-duration limits for acute gout and dental pain. | Reduces unnecessary high-dose exposure. |
| Cardiovascular risk | Product information warns that heart-attack and stroke risk can increase with prolonged treatment, especially at higher doses. | Supports lowest-effective-dose prescribing. |
| Large generic base | The UK emc currently lists dozens of etoricoxib medicines from multiple authorization holders. | Demonstrates mature generic competition in authorized markets. |
Source: Arcoxia SmPC; Aurobindo leaflet; emc ingredient list.
The market is highly genericized. Competition is driven by registration coverage, pharmacy distribution, pack sizes, manufacturing cost and tender access rather than meaningful clinical differentiation between approved products containing the same active ingredient.
Arcoxia remains the reference brand across multiple international markets and is available in several tablet strengths.
Large generic companies compete through broad product dossiers, pharmacy supply and price.
Regional and international generic manufacturers use lower-cost production and large domestic distribution networks to expand access.
Source: Arcoxia; emc products; Aurobindo; Viatris.
April 2026: Aurobindo/Milpharm’s UK etoricoxib patient information was updated on the electronic medicines compendium, reflecting continued active generic supply across 30 mg, 60 mg, 90 mg and 120 mg strengths.
2026: The UK electronic medicines compendium continued to list more than 30 etoricoxib products across Organon and multiple generic authorization holders.
2026: Current product information continued to emphasize indication-specific dosing and lowest-effective-dose treatment because cardiovascular risk rises with longer exposure and higher doses.
2026: Ongoing generic availability across Europe and Asia continued to shift competition toward price, pharmacy access and supply reliability rather than new formulation innovation.
Source: Aurobindo product; emc ingredient list; Arcoxia SmPC.
The global etoricoxib tablet market market is projected to grow from USD 1.30 billion in 2026 to USD 2.50 billion by 2034, at a 8.5% CAGR during 2026–2034. Growth is expected to be supported by aging populations, high osteoarthritis prevalence and wider access to low-cost generics in Asia-Pacific and other authorized markets. Value growth will remain constrained by intense price competition and safety-driven prescribing limits.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Osteoarthritis burden | WHO estimates 528 million people live with osteoarthritis. | Creates a large chronic pain-treatment population. |
| Generic penetration | Many approved suppliers compete across multiple strengths. | Expands access while compressing price. |
| Asia-Pacific scale | Large populations and generic manufacturing support the largest regional market. | Drives volume growth. |
| Online pharmacy | Digital fulfillment improves chronic refill access. | Supports distribution expansion. |
| Safety management | Lowest-effective-dose guidance limits excessive long-duration high-dose use. | Shapes realistic treatment patterns. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global etoricoxib tablet market landscape.
24LifeScience develops etoricoxib tablet market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines current product-label information, WHO musculoskeletal-disease evidence and current authorized-product listings. Market sizing uses a 2025 base year, 2026 estimate and 2034 forecast with 2026–2034 CAGR mathematically reconciled to the displayed endpoints.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 1.20 billion in 2025 and is estimated at USD 1.30 billion in 2026. It is projected to reach USD 2.50 billion by 2034 at an 8.5% CAGR during 2026–2034.
Etoricoxib is a selective COX-2 inhibitor used in authorized markets for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gout and selected acute pain.
The 60 mg strength leads because it is widely used across chronic inflammatory indications and is a common ongoing dose.
Osteoarthritis is the largest application because of its very large global disease burden.
Asia-Pacific is the largest regional market, supported by high disease burden, generic manufacturing and broad local availability.
Cardiovascular, renal and gastrointestinal risks require appropriate patient selection and use of the lowest effective dose for the shortest suitable duration.
The market is highly genericized, with competition focused on price, regulatory coverage, pack sizes and pharmacy distribution.
The report profiles Organon, Aurobindo, Viatris, Zentiva, Glenmark, Strides, Krka, Sun Pharma, Cipla, Dr. Reddy’s and Qilu Pharmaceutical.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.